HIGHLIGHTS
- who: Rayan Berabez and collaborators from the Institut de Chimie Organique et Analytique, University of Orléans, CNRS UMR, have published the paper: LIM Kinases, Promising but Reluctant Therapeutic Targets: Chemistry and Preclinical Validation In Vivo, in the Journal: Cells 2022, 2090 of 13/06/2022
- what: Throughout this review, we have seen that LIM kinases are indeed promising but reluctant therapeutic targets.
- how: To further To differentiate between the active the active compounds they were tested for their inhibition of cofilin phosphorylation in compounds they were tested for their inhibition of cofilin . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.